At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 730 enrolled
Drug / intervention
Cabozantinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Discontinuation Study of XL184 in Subjects With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating Cabozantinib and Placebo for Solid Tumors and Cancer. Completed, enrolled 730 participants across 47 sites in 5 countries.
Detailed Summary
This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors, Cancer
CountriesBelgium, Israel, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2009
Enrollment StartSep 2009
Primary CompletionMay 2013
Study CompletionJun 2014
TodayJul 2026
First PostedJul 15, 2009
Enrollment StartSep 1, 2009
Primary CompletionMay 1, 2013
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 17.0 years ago
Interventions
Cabozantinibdrug
Placebodrug